Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
About Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
19
Genentech, Inc.
3
Pfizer
2
Clinical Trials at Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
During the past decade, Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2 conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 15 clinical trials were completed, i.e. on
average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 4 clinical trials were completed. i.e. 400%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
2007-08-01
2017-09-07
Completed
674
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
2008-09-03
2016-02-25
Completed
723
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
2010-04-30
2018-11-30
Completed
413
A Study of Vemurafenib in Participants With Metastatic Melanoma
2011-03-01
2016-02-24
Completed
3,219
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
2011-12-06
2017-10-31
Completed
30
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
2012-01-11
2022-08-31
Completed
273
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
2012-05-17
2020-02-19
Completed
2,577
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
2012-09-27
2019-02-07
Completed
231
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2"
#1 collaborator was "Chugai" with 1 trials as a collaborator, "Exelixis" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 3 trials.
Clinical Trials Conditions at Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
According to Clinical.Site data, the most researched conditions in "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2" are
"Bladder Cancer" (3 trials), "Kidney Neoplasms" (2 trials), "Malignant Melanoma" (2 trials), "Prostate Cancer" (2 trials) and "Renal Cell Carcinoma" (2 trials). Many other conditions were trialed in "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2" in a lesser frequency.
Clinical Trials Intervention Types at Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
Most popular intervention types in "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2" are "Drug" (23 trials) and "Other" (3 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (11 trials), "Placebo" (5 trials), "Cisplatin" (3 trials), "Abiraterone" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
The vast majority of trials in "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2" are
21 trials for "All" genders and 3 trials for "Male" genders.
Clinical Trials Status at Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
Currently, there are NaN active trials in "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2".
undefined are not yet recruiting,
undefined are recruiting,
5 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 17 completed trials in Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, 3 "Phase 1"
clinical trials were conducted, 6 "Phase 2" clinical
trials and 15 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".